2 Gansevoort Street
9th Floor
New York, NY 10014
United States
212 554 4484
https://www.tgtherapeutics.com
Sector(s):Â Healthcare
Industry:Â Biotechnology
Full Time Employees:Â 286
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Michael S. Weiss Esq. | Chairman, CEO & Pres | 2.07M | N/A | 1966 |
Mr. Sean A. Power CPA, CPA | CFO, Corp. Sec. & Treasurer | 570.36k | N/A | 1982 |
Dr. Owen A. O'Connor | Chief Scientific Officer | N/A | N/A | N/A |
Jenna Bosco | Sr. VP of Corp. Communications | N/A | N/A | N/A |
Mr. Adam Waldman | Chief Commercialization Officer | N/A | N/A | N/A |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
TG Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2022 is 10. The pillar scores are Audit: 9; Board: 10; Shareholder Rights: 4; Compensation: 10.